Tencent Launches TenPayGo Payment App for Foreign Tourists in China 
Airbus Finds A321neo Fuselage Quality Issue 
Akamai Shares Surge on $11.6B Anthropic AI Cloud Deal 
China Reviews Broadcom Switch Use in State Data Centres 
Meta Unveils Muse Charm AI Device, Expands Smart Glasses Lineup 
Meta Connect Spotlights Camera-Free Smart Glasses Amid Privacy Concerns 
BMW 2028 Margin Target Could Fall Below Consensus, UBS Says 
Costco Revenue Beats Estimates as Inflation Drives Bulk Shopping 
McDonald’s Sees Flat Traffic, Sticky Inflation as New Normal 
Tesla Semi Rollout Begins at Nevada Factory 
SoftBank Raises $11.1 Billion in Bond Sale to Fund OpenAI Investment 
H&M Q3 Profit Beats Estimates as Margins Improve 
Microsoft Stock Upgraded as Stifel Sees Stronger Azure Growth 
Former OpenAI Data Center Chief Chris Malone Joins Nvidia 
US Northeast Airports Resume Operations After Telecom Outage Disrupts Thousands of Flights 
JPMorgan Names Lavatelli Japan Chief in Leadership Shake-Up 
Add as a preferred source on Google
Merck Group announced on Wednesday, March 24, that it has assigned a new chief financial officer. The company picked Caroline Litchfield to be Robert Davis’s replacement and she will assume her post starting April 1.
Litchfield’s new appointment at the company
As per Reuters, Litchfield has been working for Merck since 1990. At that time, she joined the company as part of its unit in the U.K. Prior to her new assignment as CFO this year, she was in charge of Merck’s treasury, tax and investor relations.
She has also worked in the financial operations section for Merck’s Human Health. This unit is the pharmaceutical firm’s largest business to date.
In any case, she will be succeeding Rob Davis, who will leave his post as CFO. He will be taking over as the company’s new chief executive officer as the current CEO, Ken Frazier, already announced last month that he is retiring in June.
Litchfield’s expected contribution as the new CFO
The new assignments of chief officers also come as Merck is aiming for transformation. It wanted to diversify its offerings and go beyond the immuno-oncology business development. It was mentioned that Litchfield would be a big help in this transition as she takes on part of the responsibilities for this plan.
“Caroline’s appointment as our next CFO is the result of a combination of factors and most importantly, Caroline’s financial expertise, remarkable track record, and leadership as well as our commitment to developing talent and our succession planning for leadership roles,” Kenneth C. Frazier said in a press release.
Davis added, “Caroline’s passion for Merck’s mission and for the patients we serve guides every decision that she makes." He said he is also looking forward to working with Caroline and "to benefit from her expertise and leadership as we chart the course for Merck in the months and years ahead.”
In response to the warm welcome from her colleagues, Caroline Litchfield said that she is very honored to serve Merck as the new CFO. She went on to say that her assignment is even more meaningful as it comes at such a pivotal time when the company is transitioning to improve lives.
